贝达基林的群体药理动力学:一个系统的审查
Jie Jin1, Jie Cao1, Ruoying Zhang1
1Department of Pharmacy, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, 310000, Zhejiang, China.
贝达基林 (BDQ) 的药理动力学显示出显著的变化. 体重,种族,白蛋白和其他药物等因素会影响BDQ清除,这对于优化多药耐药结核病 (MDR-TB) 治疗至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 结核病研究 结核病研究
- 临床药房 临床药房
背景情况:
- 贝达基林 (BDQ) 对于治疗多抗药结核病 (MDR-TB) 是至关重要的.
- 显著的药理动力学 (PK) 变异性使BDQ的临床应用复杂化.
- 了解影响BDQ PK的因素对于有效治疗至关重要.
研究的目的:
- 为了整合BDQ的种群药理动力学 (PPK) 数据.
- 确定解释 BDQ 的 PK 变异性的关键共变量.
主要方法:
- 对PubMed和Web of Science数据库的系统文献审查,截至2023年10月1日.
- 鉴定和分析BDQ的种群药理动力学 (PPK) 研究.
- 从包括的研究中总结了PK特征和显著的共变量.
主要成果:
- 分析了8项成人和1项儿科研究.
- 通常使用的是具有动态吸收的三模型.
- 重要的共同变量包括体重,种族,白蛋白和同时服用的药物.
- 增加的体重和白蛋白与更高的BDQ清除 (CL) 相关联.
- 儿科患者的CL每体重高于成人的1.49倍.
- 黑人患者的CL高出84%.
- 同时使用利法素和利法丁增加了BDQ CL,分别增加了378%和296%.
结论:
- 体重,种族,白蛋白水平和同时服用的药物显著影响BDQ暴露.
- 需要进一步的PPK研究来完善BDQ的剂量策略.
- 优化BDQ疗法可以改善MDR-TB的治疗结果.
更多相关视频
12:17An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
Published on: May 8, 2017
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Analysis of Population Pharmacokinetic Data
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
